APA (7th ed.) Citation

Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., . . . Blohmer, J. (2013). The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Annals of oncology, 24(3), .

Chicago Style (17th ed.) Citation

Eiermann, Wolfgang, et al. "The 21-gene Recurrence Score Assay Impacts Adjuvant Therapy Recommendations for ER-positive, Node-negative and Node-positive Early Breast Cancer Resulting in a Risk-adapted Change in Chemotherapy Use." Annals of Oncology 24, no. 3 (2013).

MLA (9th ed.) Citation

Eiermann, Wolfgang, et al. "The 21-gene Recurrence Score Assay Impacts Adjuvant Therapy Recommendations for ER-positive, Node-negative and Node-positive Early Breast Cancer Resulting in a Risk-adapted Change in Chemotherapy Use." Annals of Oncology, vol. 24, no. 3, 2013.